Table 1.
A) Significance of vasoconstriction in response to cumulative doses of ANG II between control, BV6(K+)2, BV6(Na+)2, and BV6(TFA)2 incubations obtained from Fig. 2A.
log[ANGII], M | Control vs. BV6(K+)2 | Control vs. BV6(Na+) | Control vs. BV6(TFA) |
---|---|---|---|
−12.0 | No significance | No significance | No significance |
−11.5 | No significance | No significance | No significance |
−11.0 | No significance | * p = 0.0493 | * p = 0.0186 |
−10.5 | *** p = 0.0002 | *** p = 0.0009 | *** p = 0.0009 |
−10.0 | **** p < 0.0001 | **** p < 0.0001 | **** p < 0.0001 |
−9.5 | **** p < 0.0001 | **** p < 0.0001 | **** p < 0.0001 |
−9.0 | **** p < 0.0001 | **** p < 0.0001 | **** p < 0.0001 |
−8.5 | **** p < 0.0001 | **** p < 0.0001 | **** p < 0.0001 |
−8.0 | **** p < 0.0001 | **** p < 0.0001 | **** p < 0.0001 |
−7.5 | **** p < 0.0001 | **** p < 0.0001 | **** p < 0.0001 |
−7.0 | **** p < 0.0001 | **** p < 0.0001 | **** p < 0.0001 |
−6.5 | No significance | *** p = 0.0003 | * p = 0.0126 |
−6.0 | No significance | * p = 0.0135 | No significance |
−5.5 | No significance | No significance | No significance |
−5.0 | No significance | No significance | No significance |
B) Hill coefficients for angiotensin contraction of rat smooth muscle tissues in the absence and presence* of sarilesin (20nM). | ||
---|---|---|
Tissue | Absence of [Sar1Ile8]ANG II | Presence of [Sar1Ile8]ANG II |
Uterus | 1.4 | 0.8* |
Portal vein | 1.7 | 0.8* |
Aorta | 1.9 | 0.9* |